SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending as investors react to preliminary revenue numbers that fell short of guidance, with some sales pushed to the next quarter due to design upgrades. The community is debating whether this is a buying opportunity or a sign of deeper issues, while also discussing revenue recognition and potential management changes. Despite the dip, some bulls remain optimistic about the company's overall prospects in the AI server market.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending amid reports of potential government equity stakes in quantum computing firms, sparking excitement and high trading volume. The community is buzzing about the implications of government funding and its potential to legitimize the sector, while some express skepticism, pointing to existing offerings. Discussions also involve comparisons to other quantum computing stocks and speculation about the long-term viability of the technology.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending as investors digest strong Q3 earnings and a raised outlook, though some are concerned about slowing software growth. The community is discussing IBM's potential in AI and quantum computing, particularly after a partnership with HSBC and recent analyst upgrades. Despite some skepticism, bulls view IBM as undervalued with long-term growth potential in these innovative sectors.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending due to speculation around government investment in the quantum computing sector, potentially mirroring a move towards nationalizing key technologies. The community is actively debating whether this rumored government interest will lead to a short squeeze or if the stock is overhyped, with some warning of a potential pump and dump scenario amid broader concerns about the sector's long-term profitability.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending following positive earnings reports and analysts raising price targets, citing accelerated obesity trials and an upcoming FDA meeting. The community is actively discussing the potential for a short squeeze and speculation around possible M&A activity related to their MASH asset. Bullish sentiment is driven by optimism around their obesity drug pipeline and potential as a strategic target for big pharma.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences ($VTYX) is trending following positive Phase 2 trial results for its obesity and cardiovascular risk drug, leading to significant premarket gains. The community is buzzing about the potential for a buyout by a major pharmaceutical company, particularly Sanofi, given existing collaborations and the drug's promising data. Discussions also revolve around the company's strong cash position and potential dilution concerns.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is surging amid reports that the Trump administration is considering taking equity stakes in quantum computing firms. The community is buzzing about the potential implications of government involvement in the sector, with some seeing it as a bullish signal, while others express skepticism about the financial impact of a potential deal.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending amid mixed reactions to recent earnings, with discussions focusing on revenue growth versus net income drop and shrinking margins; the community is also weighing in on Elon Musk's vision for robotics and its potential impact. Additionally, some are pointing to potential challenges from competitors and changing market dynamics within the EV sector as key discussion points.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amid speculation and discussion around potential government investment in quantum computing firms, spurred by a recent report. The community is debating the validity and impact of this news, with some anticipating a boost for the sector while others express skepticism, citing past offerings and the size of the potential investment relative to company valuations. Broader discussions involve the future of quantum computing and its strategic importance.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is gaining traction as community members rally around the OG meme coin, emphasizing its strong community and culture over traditional charts. The community is expressing bullish sentiment, anticipating a moonshot and encouraging others to embrace the 'RAGE' mentality within the crypto space. Discussions highlight the importance of memes in the current market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note

Novavax (NVAX) closed the most recent trading day at $8.46, moving 1.51% from the previous trading session.

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with...

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights

Novavax (NVAX) reached $8.48 at the closing of the latest trading day, reflecting a -4.83% change compared to its last close.

Novavax (NVAX) shares traded 1% higher in the pre-market session on Tuesday after its second-largest shareholder, Shah Capital, called for the sale of the company, citing persistent underperformance.Shah Capital currently owns 11.8 million shares or 7.2% of Novavax. The firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.shahcapital.com/shah-capital-calls-for-sale-of-novavax/">said</a> in a letter to the Novavax board of directors that since March 2023, its concerns have accelerated with “Nuvoxovid’s rollout slipups including this fall, timid/ineffective marketing, extremely poor capital market actions, and tremendous lack of accountability.”“Novavax’s IP and scientific capabilities will have far greater upside potential in the hands of large capable pharma entity,” Shah Capital said, while recommending an immediate formal strategic review for the sale of the company.The investor recapped several alleged missteps that have damaged the company, including critical marketing slips resulting in a small 2% Covid vaccine market share in the 2024 season for Novavax’s protein-based Nuvaxovid vaccine.Shah Capital also expressed surprise at Nuvaxovid’s market share, noting that the increasing criticism for mRNA vaccines made by Novavax’s peers should benefit Novavax’s protein-based vaccine.“With more states becoming increasingly averse to mRNA vaccines including Florida, Texas, Minnesota, Idaho, Iowa, Montana, South Carolina, Tennessee &amp; Kentucky; some of which are trying to ban mRNA altogether, we find it inconceivable as to how management has been unsuccessful gaining meaningful share given the tens of millions of senior citizens/high risk/immunocompromised individuals in just those 9 states alone. Sales are miserable for the third consecutive year,” it said.The investor also noted that awareness regarding Nuvaxovid continues to be “alarmingly low.” Shah further alleged that the “execution failure and ineffective leadership” have taken their toll on investor confidence and trust.Last year, Shah Capital waged a proxy campaign against the re-election of some directors on the company board at Novavax’s 2024 Annual Meeting, but withdrew it after the company struck a licensing agreement with Sanofi.Sanofi is Novavax’s biggest partner. In the second quarter (Q2), the $199 million received from Sanofi accounted for over 83% of Novavax’s total revenue of $239 million.<a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> is up by 7% this year but down by about 32% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-appoints-ceo-charlie-scharf-as-chairman-after-q3-earnings-beat-estimates/ch6mVM6R3mE">Wells Fargo Appoints CEO Charlie Scharf As Chairman After Q3 Earnings Beat Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity

Shah Capital currently owns 11.8 million shares or 7.2% of Novavax.

Equity

Shah Capital currently owns 11.8 million shares or 7.2% of Novavax.


Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade

Novavax (NVAX) closed the most recent trading day at $9.08, moving 4.02% from the previous trading session.

Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw Novavax (NVAX) settling at $8.67, representing a +1.17% change from its previous close.

Novavax, Inc. (NVAX) on Tuesday said that it has amended its collaboration and license agreement with Sanofi (SNY) to include the use of its Matrix-M adjuvant in Sanofi's pandemic influenza vaccine candidate program.The amendment of the agreement allows for the use of Matrix-M in early-stage development of Sanofi's pandemic influenza vaccine candidate. The two players will negotiate license rates and financial terms if the program enters late-stage study, Novavax <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.novavax.com/press-releases/2025-09-30-Novavax-Announces-Progress-on-Sanofi-Agreement">said</a>.Matrix-M is Novavax's proprietary adjuvant that can be added to a vaccine to stimulate a stronger immune response and is currently used in globally approved vaccines. Sanofi is currently exploring additional opportunities with Matrix-M, Novavax said.<a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> traded 1.4% lower on Tuesday morning and was among the top trending tickers on Stocktwits. On Stocktwits, retail sentiment around NVAX stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user opined that the agreement is a long-term payout play.<stembedurl>https://stocktwits.com/DifferentRadar/message/630462629</stembedurl>The new amendment adds to the terms of the original agreement between the two companies, dated May 2024. Under the agreement, Novavax is entitled to receive up to $200 million for the first four products created by Sanofi utilizing its Matrix-M adjuvant, and up to $210 million in milestone payments for each product including Matrix-M thereafter. Novavax is also eligible to receive royalties for all Sanofi products utilizing Matrix-M.Sanofi is Novavax’s biggest partner. In the second quarter, the $199 million received from Sanofi accounted for over 83% of Novavax’s total revenue of $239 million.NVAX stock is up by 5% this year but down by 33% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-gets-price-target-hike-from-canaccord/chDD7JrR3Bq">Tesla Gets A Price Target Hike From Canaccord: Retail Sees Stock Touching New Highs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a covid-19 vaccine is seen with the Novavax logo in the background. (Photo Illustration by Nikos Pekiaridis/NurPhoto via Getty Images)

Novavax Amends Deal With Sanofi, Broadens Partnership

The amendment of the agreement allows for the use of Matrix-M in early-stage development of Sanofi's pandemic influenza vaccine candidate.

Here's Why Novavax (NVAX) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

NVAX
Novavax Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVAX News

NVAXNovavax Inc